Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma
A phase 3 trial testing TBI-1301 in sarcomas, now recruiting.
Overview
Multi-centre Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma is a phase 3 interventional study registered as NCT07174427, led by Takara Bio, and recruiting when checked on 2026-09-11. Official title: Multi-centre Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma. Planned enrolment is 5 participants (estimated). The study started in 2026-01-05 and primary completion is expected in 2032-03. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
Shares Sarcomas (soft tissue, bone, GIST) and the tag ctgov-ingest.
- TreatmentINT230-6
Shares Sarcomas (soft tissue, bone, GIST) and the tag ctgov-ingest.
- TreatmentT3011
Shares Sarcomas (soft tissue, bone, GIST) and the tag ctgov-ingest.
- TreatmentHS-20093
Shares Sarcomas (soft tissue, bone, GIST) and the tag ctgov-ingest.
- TreatmentGotistobart
Shares Sarcomas (soft tissue, bone, GIST) and the tag ctgov-ingest.